2016_Head & Neck COURSE BOOK

Our experience ADENOCARCINOMA

Previous treatment (S and/or RT and/or CHT) 25%

EER ERTC CER

38 (22.5%) 103 (60.9%) 28 (16.6%)

Pathological stage

pT0 pT1 pT2 pT3

1 34 48 32 11 43

(0.6%) (20.1%) (28.4%) (18.9%) (6.6%) (25.4%)

Positive margins 18 ( 10.6% ) 3 pT3, 1 pT4a, 14 pT4b

pT4a pT4b

Adjuvant RT 99 ( 58.6 %)

Nicolai et al, Head Neck 2015

mercoledì 29 giugno 16